Trial Profile
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Erlotinib (Primary) ; Etoposide (Primary) ; Methotrexate (Primary) ; Topotecan (Primary) ; Topotecan (Primary) ; Vinblastine (Primary) ; Vincristine (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; Brain cancer; Carcinoma; CNS cancer; Ependymoma; Glioblastoma; Glioma; Gliosarcoma; Medulloblastoma; Neuroblastoma; Neuroepithelial neoplasms; Oligodendroglioma; Primitive neuroectodermal tumours; Rhabdoid tumour
- Focus Pharmacodynamics; Therapeutic Use
- 05 May 2023 Planned End Date changed from 30 Apr 2023 to 1 Apr 2026.
- 22 May 2017 Planned End Date changed from 31 Dec 2023 to 30 Apr 2023.
- 22 May 2017 Planned primary completion date changed from 31 Dec 2018 to 30 Apr 2018.